Litcius/Paper detail

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan, Joshua R. Dahlke, Jay B. Fell, John P. Fischer, Robin J. Gunn, Jill Hallin, Jade Laguer, J. David Lawson, James Medwid, Brad Newhouse, Phong Nguyen, Jacob M. O’Leary, Peter Olson, Spencer Pajk, Lisa Rahbæk, Mareli Rodriguez, Christopher R. Smith, Tony P. Tang, Nicole C. Thomas, Darin Vanderpool, Guy Vigers, James G. Christensen, Matthew A. Marx

2021Journal of Medicinal Chemistry710 citationsDOIOpen Access PDF

Abstract

mutant xenograft mouse tumor model.

Topics & Concepts

KRASChemistryMutantCancer researchMutationBiochemistryBiologyGeneProtein Kinase Regulation and GTPase SignalingEnzyme Structure and FunctionMelanoma and MAPK Pathways
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor | Litcius